CJC-1295 NO DAC
Description – CJC-1295 NO-DAC
CJC-1295 NO-DAC is a synthetic peptide developed to be an analogy of growth hormone-releasing hormone (GHRH)1. The 29 amino acid sequence is derived from GRF(1-29), a naturally occurring growth hormone-releasing factor. As its name implies, CJC-1295 no DAC lacks the ‘drug affinity complex’ described below2. This structural difference infers a shorter peptide half-life than its DAC-inclusive counterpart, which elicits a GH release profile that more closely reflects what occurs in nature. CJC-1295 no DAC is reported to be a potent agent for the stimulation of pulsatile growth hormone (GH) and IGF-1 release3. These biochemical actions have been shown to result in the promotion of lean body mass, enhanced strength, increased appetite, and improved quality of sleep in animal test subjects4.
Product Comparison – CJC-1295 NO-DAC
In spite of having a similar site of action, CJC-1295 no DAC (and CJC-1295 with DAC) does not stimulate GH production using the same biochemical pathway as the popular GH secretagogue GHRP-65. In light of this observation, it has been possible for researchers to administrate CJC-1295 species and GHRP-6 concurrently in order to achieve an additive positive effect on GH release.
Drug Affinity Complex – CJC-1295 NO-DAC
The drug affinity complex (DAC) is a chemical group fixed to CJC-1295 DAC that helps the peptide escape degradation by natural enzymes. By adding a component that gives CJC-1295 an affinity for albumin2, a naturally occurring protein in blood plasma, the peptide can achieve a much longer systemic half-life.
Preference for a long or short peptide half-life depends entirely on the research application of these agents.
Research products only, they are not for human consumption.
Synonyms:
CJC-1295; CJC-1295 no-DAC; CJC-1295 without DAC; Modified Growth Releasing Factor aminos 1-29; CJC1295 NO-DAC; Modified GRF (1-29); Mod GRF 1-29; Tetrasubstituted GRF (1-29);
Peer-Reviewed Sources:
Sackmann-Sala, L., Ding, J., Frohman, L. A., & Kopchick, J. J. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471-477.
Beals, J. M., & Shanafelt, A. B. (2006). Enhancing exposure of protein therapeutics. Drug Discovery Today: Technologies, 3(1), 87-94.
Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805.
Alba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J. P., Frohman, L. A., & Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism, 291(6), E1290-E1294.
Cordido, F., Penalva, A., Dieguez, C., & Casanueva, F. F. (1993). Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity. The Journal of Clinical Endocrinology & Metabolism, 76(4), 819-823.
ALL LITERATURE, INFORMATION, AND DATA, PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.